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ENdOThELIAL dYsfUNcTION ANd cARdIOVAscULAR  
RIsK IN PATIENTs WITh ANKYLOsING sPONdYLITIs
S. I. Smiyan, B. O. Koshak, I. V. Gnatko
I. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
Background. Ankylosing spondylitis is a disease that induces damage to the musculoskeletal system. Mortality 
rate among patients with AS is in 1.5 times higher than the population level. It is caused by cardiovascular disease 
and chronic renal failure.
Objective. The research was aimed to study the prevalence of endothelial dysfunction and to establish its 
dependence on the factors of cardiovascular risk in patients with AS.
Methods. 104 patients with ankylosing spondylitis (AS) were examined using standard diagnostic methods, 
such as disease activity, lipidogram, ultrasound of the carotid artery intima media, and endothelium vasodilatation 
in response to reactive hyperaemia was evaluated. Clinical activity of the disease was determined using the disease 
activity index BASDAI, BASFI functional index, index BASMI metrology, ASQoL quality of life. To estimate the 10-
year risk of cardiovascular disease, the QRISK scale was used.
Results. Endothelial dysfunction (ED) was found in 47% cases. It was established that in the patients with 
ED<10% the incidence of LPL>1.7 mg/L, HDL-C<1.0 mmol/L, TIM thickening>0.9 mm was higher than in the patients 
with ED>10%. In this group of patients, significant duration of the disease and essential differences in their 
progress in terms of VAS, CRP, ESR, index activity and functional disorders were revealed.
Conclusions. The problem of CVD in patients with AS may be caused by systemic inflammatory disease 
associated with the development of endothelial dysfunction and increased levels of atherogenic lipids.
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Introduction
Ankylosing spondylitis (AS) is a chronic sys-
temic inflammatory disease primarily involving 
the axial skeleton (sacroiliac, intervertebral 
joints) [1; 12] and belongs to the group of sero-
negative spondylitis (SnA).
Mortality among patients with AS is in 1.5 
times higher than the population levels. [8] It 
is caused by cardiovascular disease and chronic 
renal failure [3]. It is established that the pre-
sence of chronic systemic inflammation is an 
important predictor of cardiovascular (CV) dise-
ase [5; 7; 12] due to the development of endo-
thelial dysfunction, and further – atherosclerosis 
and atherothrombosis, remodelling of vascular 
wall and myocardium [10] and, therefore, the 
main cause of numerous life-threatening ad-
verse conditions.
Specifics of endothelial dysfunction deve­
lopment have been well studied in patients with 
rheumatoid arthritis, systemic lupus erythe-
matosus. At the same time, despite widespread 
prevalence of AS, this aspect has not been 
discussed and analyzed in a cohort of these 
patients so far. There is scanty information of 
the impact of systemic inflammation activity on 
the functional state of endothelium in cases of 
AS, and of the possibility of endothelial dysfun-
ction correction against the background of 
anti­inflammatory therapy. The research was 
aimed to study the prevalence of endothelial 
dysfunction and to establish its dependence on 
the factors of cardiovascular risk in patients 
with AS.
Methods
104 patients (90 males and 14 females) with 
verified diagnosis of AS were examined. They 
were hospitalized into the Department of 
Rheumatology of Ternopil University Hospital 
within 2015-2017. The study inclusion criteria 
were: the diagnosis of AS according to the 
modified New York criteria and the informative 
patient’s consent to participate in the study. 
Exclusion criteria were age over 60 years old, 
presence of psoriasis, Crohn’s disease, ulce­
rative colitis, coronary heart disease, mani fes-
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tations of peripheral atherosclerosis, clinically 
significant heart disease, circulatory insuffi­
ciency of any origin, diabetes, severe liver 
disease, kidney diseases and other chronic 
diseases in their acute phases. All patients who 
agreed to participate in the study underwent 
general clinical examination (common blood 
test, urinalysis, ECG, X-ray of sacroiliac joints), 
biochemical test of blood with determination 
of lipidograma and acute phase indicators 
(C-reactive protein, rheumatoid factor and etc.) 
and detection of HLA B-27. Clinical activity of 
the disease was determined using the disease 
activity index BASDAI, BASFI functional index 
and BASMI metrology index, ASQoL quality of 
life [2, 4]. Endothelium vasodilatation was 
evaluated in response to reactive hyperaemia 
in 57 patients by the method, which was first 
described by D. Celermajer [9], using Acuson 
128 XP/10 ultrasonic complex equipped with a 
7 MHz linear transducer. The study was con-
ducted in a duplex mode (ultrasound scanning 
in B-mode and Doppler spectral analysis of the 
signal). Tests with reactive hyperaemia (endo-
thelium-dependent vasodilators) and nitro-gly-
cerine (endothelium-independent vasodilators) 
were performed [10].
Endothelium-dependent vasodilatation 
(EDVD) was calculated by the formula: 
EDVD=(d60–d0)×100%/d0, where d60 is the 
brachial artery diameter 60 seconds after the 
restoration of blood flow, d0 – the initial dia­
meter of brachial artery. Endothelium-indepen-
dent vasodilatation (EIVD) was calculated by the 
formula: EIVD=(d5–d0)×100%/d0, where d5 – 
the diameter of brachial artery after 5 minutes 
of taking nitro-glycerine, d0 – the initial dia-
meter of brachial artery.
To determine the correlation between EIVD 
and EDVD, the reactivity index (IR) of brachial 
artery was calculated using the formula: 
IR=EIVD/EDVD. To assess the 10-year risk of 
cardiovascular disease, the scale QRISK was 
used (Q-RESEARCH Cardiovascular Risk Algo-
rithm). The advantage of this scale is the use of 
such risk factors: age, sex, smoking, systolic 
blood pressure, the ratio of total cholesterol 
and HDL cholesterol, body mass index, family 
history of coronary artery disease, socio eco no-
mic status, treatment with antihypertensive 
drugs and the presence of comorbidity, sys-
temic inflammatory disease in an individual 
case.
Statistical analysis of the results was carried 
out using traditional methods of ANOVA, SPSS 
22 (© SPSS Inc.).
Results
The main part of patients was of working 
age (mean age – 35.9±17.1 years old, duration 
of the disease averaged 15.9±8.2 years (Fig. 1)). 
Peripheral form of the disease was found in 35 
patients (33.7%), central form – in 69 patients 
(66.3%). Evaluation of the disease proved the 
presence of high and moderate activity in the 
absence of disease in patients who had inactive 
or active course.
Fig. 1. Classification of patients according to age and 
disease duration
The research of endothelium functions in 
the patients with AS and in the control group 
proved that remodulation of vessels occurred 
due to endothelium dilation of brachial artery 
in response to reactive hyperaemia and that 
they differ slightly in the quantitative value of 
the indicator in the control group. Besides, 
EDVD reduced (less than 10%), that is a sign of 
endothelial dysfunction, more common among 
patients with AS as compared to the control 
group (45.7% vs. 11.8%, respectively). EIVD is 
significantly higher than EDVD in patients with 
AS and healthy individuals. However, EIVD in 
the patients with AS was found to exceed 
significantly the EDVD in the control group 
(Table 1).
In what follows, we evaluated clinical and 
laboratory characteristics of AS in patients with 
reduced EIVD (Table 2). The data proved that 
in the patients with impaired endothelial 
vasoregulation function, a significantly longer 
duration of disease was revealed, the onset of 
the illness symptoms was evidenced in younger 
S. I. Smiyan et al.
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age. In addition, the patients with impaired 
EDVD had significantly higher indices of VAS 
and activity (BASDAI) with significantly higher 
than quantitative indicators of CRP, ESR, func-
tional disorders and DFI.
Among the patients with EIVD<10% (26 
patients), 14 (53.8%) are treated with NSAIDs, 
only 4 (28.5%) of them – continuously. Among 
the patients with EDVD>10% (31 patients), 28 
persons underwent NSAIDS therapy, 19 of 
them – continuously (Fig. 2)
Classical cardiovascular risk factors and 
arterial hypertension are crucial for the devel-
opment of endothelial dysfunction, so their 
prevalence in the group of the examined pa-
tients was analysed (Table 3).
About every third patient suffered from II 
degree hypertension, and the frequency of its 
registration was found to be similar to the 
prevalence among the general population (in 
the city area – 29.3%, in rural – the prevalence 
of hypertension – 36.3%) [13].
It should be noted that adequate antihyper-
tensive therapy at the time of inclusion into the 
study was provided for 14 patients (39%). 
Thickening of intima-media common carotid 
artery >1 mm was found in 19.2% patients with 
AS. High incidence of smoking among patients 
with AS can be due to the predominance of 
males. Many patients had reduced levels of HDL 
and high LDL levels that can be attributed to 
scanty availability of patients with hypercho-
lesterolemia.
Mean BMI in the studied patients was 
20.2±4.9 kg/m2; 72 (69.2%) patients had normal 
weight (BMI 18.5-24.9 kg/m2), 18 (17.3%) pa ti ents 
had a deficit of body weight (BMI<18.5 kg/m2), 
Table 1. Results of endothelia vasoregulation function
Indices АS (n=57) The control group (n=20) p
The initial diameter of brachial artery, mm 4.32±0.29 3.78±0.18 p<0.05
The wall thickness of brachial artery, mm 0.58±0.06 0.41±0.03 p<0.05
The output speed of blood flow, m/s 0.72±0.09 0.68±0.07 p<0.05
EDVD, % 9.8±1.23 13.3±1.1 p<0.05
EIVD, % 25.4±2.14 19.7±5.4 p<0.05
Brachial artery reactivity index 2.35±0.12 1.37±0.14 p<0.05
Note: p – significant differences between the baselines indicators of the study and control groups.
Table 2. Clinical and laboratory characteristics of patients with AS
Indices EDVD>10%(n=31)
EDVD<10%
(n=26) p
Disease duration, (yrs) 13.7±5.2 16.1±4.8 p>0.05
Age of disease onset, (yrs) 25.8±3.2 23.2±2.1 p>0.05
The presence of peripheral arthritis n % n % p>0.05
10 32.3 9 34.6
BASDAI, sm 4.64±0.42 6.80±0.27 p<0.05
BASFI, sm 4.34±0.28 5.74±0.18 p<0.05
DFI, points 15.8±1.1 17.1±0.89 p<0.05
VAS, mm 61.9±14.5 80.3±12.4 p<0.05
С­reactive, mg/l 8.3±1.4 15.2±2.7 p<0.05
ESR, mm/h 18.3±3.2 28.5±4.1 p<0.05
Note: р – significant differences between ЕD<10% and ED>10%.
Fig. 2. Dependence of EDVD on the duration of NSAID 
treatment
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and 10 (9.6%) patients had excessive body 
weight (BMI>25 kg/m2), including 4 (3.8%) with 
obesity (BMI>30 kg/m2).
The next stage of our research was aimed 
at analysing the quantitative characteristics of 
cardiovascular risk factors in patients with 
impaired EIVD (Table 4). The data proved that 
the level of atherogenic lipids (LDL and HDL) 
was the sole indicator of significant differences 
between patients with normal and impaired 
EIVD. On the other hand, it was found that 
patients in groups with normal and low EDVD 
were comparable regarding most cardiovascular 
risk factors. Thus, traditional factors are unlikely 
to play a major role in the processes of endo-
thelial wall remodullation and EDVD occurrence.
Further cardiovascular risk for the examined 
patients was established, the value for the study 
group (3.4 % [1.8; 5.4]) being about in three 
times higher than the risk value for the general 
population. It should be noted that the average 
cardiovascular risk in the patients with impaired 
EDVD was 2.8% as compared to the index in 
normal EIVD – 3.9%.
Discussion
Brachial artery active response to exogenous 
nitrate in patients with AS proves more com-
parable index of reactivity of brachial artery, 
that is indicative of the ratio between EIVD and 
EDVD. A recent research suggests that excessive 
response of brachial artery to exogenous 
nitrate in patients with AS is associated with 
deficient endogenous production of nitric oxide 
and can be regarded as a sign of endothelial 
dysfunction [5, 6]. The obtained findings prove 
Table 3. The prevalence of traditional cardiovascular risk factors
Sign n %
Arterial hypertension 23 22.1
ТІМ of common carotid artery >1 mm 49 47.1
Smoking 34 32.7
Hypercholesterolemia (TCh>5.2 mmol/l) 22 21.2
Low level of HDL (<1 mmol/l for male and <1.2 mmol/l for female) 63 60.6
High level of LDL (>3.0 mmol/l) 41 39.4
Hypertriglyceridemia (ТГ >1.7 mmol/l) 14 13.5
Overweight (BMI>25 kg/m2) 12 11.5
Family history of early heart disease 16 15.4
Table 4. Summary of cardiovascular risk factors and hypertension in patients with normal  
and reduced endothelium vasodilation
Markers EDVD >10% (n=31) EDVD <10% (n=26) р
Average age, years 36.8±8.2 38.8±8.8 p>0.05
BMI, kg/m 22.8±4.3 23.9±4.1 p>0.05
Smoking n % n %
12 39 10 38 p>0.05
History of smoking, years 10.2±2.4 9.2±1.9 p>0.05
Family history of early heart disease n % n %
6 19 4 15 p>0.05
TCh, mmol/l 4.52±0.94 4.28±0.81 p>0.05
HDL, mmol/l 1.16±0.31 0.71±0.21 p<0.05
LDL, mmol/l 2.61±0.18 3.22±0.29 p<0.05
Тg, mmol/l 1.15±0.44 1.32±0.58 p>0.05
Atherogenic index 3.4±1.21 3.9±1.26 p>0.05
ТІМ of common carotid artery, mm 0.89±0.12 1.32±0.18 p<0.05
Arterial hypertension n % n %
7 22.5 6 23.1 p>0.05
Systolic arterial pressure, mm.hg. 124.5±18.3 122.5±22.5 p>0.05
Diastolic arterial pressure, mm.hg. 78.5±14.5 76.5±18.5 p>0.05
Note: р – significant differences between ЕD<10% and ED>10%.
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that output diameter and wall thickness of 
brachial artery in the patients with AS were 
significantly higher than similar indices in the 
control group, and the rate of blood flow 
through the artery was virtually identical. This 
may evidence the signs of brachial artery 
remodelling in patients with AS, endothelium 
is crucial [5, 6].
The detected changes of lipid profile are 
typical for the patients with systemic inflam­
matory diseases, and are consistent with the 
literature [11].
It should be emphasized that a high cardio-
vascular risk in patients with AS cannot be 
explained from the standpoint of the analysis 
of classical risk factors, as they do not explain 
high incidence of patients with endothelium 
dependent vasodilatation, which is a significant 
predictor of cardiovascular problems in patients 
with inflammatory diseases of joints.
Conclusions
Our findings suggest high prevalence of ED 
in patients with AS (47% cases). ED <10% caused 
significant increase in the number of patients 
with LDL >1.7 mmol/dL, HDL-C <1.0 mmol/L, 
TIM thickening >0.9 mm. At the same time, in 
this group of patients a significantly longer 
duration of disease and substantial differences 
in the course in VAS, CRP and ESR indices, as 
well as activity index and functional disorders 
were revealed. With the QRisk score scale, SS 
risk was established as 3.4% that is about three 
times higher than the risk among the general 
population. Among the traditional factors, 
increased HDL and decreased LDL are most 
often reported. Thus, the problem of CVD is one 
of the most important aftermaths of systemic 
inflammatory disease that is associated with 
the development of endothelial dysfunction 
and increased levels of atherogenic lipids.
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